Literature DB >> 26309192

Functional capacity, health status, and inflammatory biomarker profile in a cohort of patients with chronic obstructive pulmonary disease.

Puja Kohli1, Victor Pinto-Plata, Miguel Divo, Atul Malhotra, R Scott Harris, Aili Lazaar, Aiden Flynn, Ruth Tal-Singer, Reynold A Panettieri, Bartolome Celli.   

Abstract

PURPOSE: Prior research has shown a significant relationship between 6-minute walking distance (6MWD) and health-related quality of life (HRQOL) in patients with chronic obstructive pulmonary disease (COPD). However, few studies have examined this relationship above and below the 350-m threshold that prognosticates survival and whether serum biomarkers could provide insight into the causes of quality-of-life differences above and below this threshold.
METHODS: Measures of lung function, 6MWD, and HRQOL were compared in patients with COPD. Differences in HRQOL domains and serum biomarkers were compared in patients whose 6MWD were > or < 350 m.
RESULTS: In patients walking < 350 m, scores in the physical domains of the SF-36 and the St. George's Respiratory Questionnaire (SGRQ) were significantly different from scores of their counterparts with greater 6MWD. However, there was no association between any biomarkers and the physical domains of the SF-36 and the SGRQ. In patients walking < 350 m, only the IL-8 levels were associated with lower scores in SF-36 domains of emotional role, pain, vitality, and mental health (average r = -0.702; P = .01). In contrast, in patients walking > 350 m, surfactant protein D levels were associated with higher SF-36 scores in general pain, vitality, and social functioning (average r = 0.42; P = .04).
CONCLUSIONS: In COPD, there is an association between 6MWD and the physical domains of the SF-36 and SGRQ in those patients walking < 350 m. The physical differences between patients walking < or > 350 m are not related to systemic inflammation. The association between interleukin 8 with nonphysical domains in patients with 6MWD < 350 m suggests that inflammation may play a larger role in the perceptive domain than previously recognized.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26309192      PMCID: PMC4551136          DOI: 10.1097/HCR.0000000000000123

Source DB:  PubMed          Journal:  J Cardiopulm Rehabil Prev        ISSN: 1932-7501            Impact factor:   2.081


  42 in total

1.  Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial.

Authors:  Donald P Tashkin; Bartolome R Celli; Marc Decramer; Theodore Lystig; Dacheng Liu; Steven Kesten
Journal:  COPD       Date:  2012-03-20       Impact factor: 2.409

Review 2.  Inflammation in COPD: implications for management.

Authors:  Sanjay Sethi; Donald A Mahler; Philip Marcus; Caroline A Owen; Barbara Yawn; Stephen Rennard
Journal:  Am J Med       Date:  2012-12       Impact factor: 4.965

3.  Fibrinogen, COPD and mortality in a nationally representative U.S. cohort.

Authors:  David M Mannino; Deepa Valvi; Hana Mullerova; Ruth Tal-Singer
Journal:  COPD       Date:  2012-04-11       Impact factor: 2.409

4.  Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study.

Authors:  T M L Eagan; T Ueland; P D Wagner; J A Hardie; T E Mollnes; J K Damås; P Aukrust; P S Bakke
Journal:  Eur Respir J       Date:  2009-07-30       Impact factor: 16.671

5.  Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD.

Authors:  D A Lomas; E K Silverman; L D Edwards; N W Locantore; B E Miller; D H Horstman; R Tal-Singer
Journal:  Eur Respir J       Date:  2009-01-22       Impact factor: 16.671

6.  Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease.

Authors:  Bartolome R Celli; Nicholas Locantore; Julie Yates; Ruth Tal-Singer; Bruce E Miller; Per Bakke; Peter Calverley; Harvey Coxson; Courtney Crim; Lisa D Edwards; David A Lomas; Annelyse Duvoix; William MacNee; Stephen Rennard; Edwin Silverman; Jørgen Vestbo; Emiel Wouters; Alvar Agustí
Journal:  Am J Respir Crit Care Med       Date:  2012-03-15       Impact factor: 21.405

7.  Characterisation of COPD heterogeneity in the ECLIPSE cohort.

Authors:  Alvar Agusti; Peter M A Calverley; Bartolome Celli; Harvey O Coxson; Lisa D Edwards; David A Lomas; William MacNee; Bruce E Miller; Steve Rennard; Edwin K Silverman; Ruth Tal-Singer; Emiel Wouters; Julie C Yates; Jørgen Vestbo
Journal:  Respir Res       Date:  2010-09-10

8.  Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD.

Authors:  Khaled Al-shair; Umme Kolsum; Rachel Dockry; Julie Morris; Dave Singh; Jørgen Vestbo
Journal:  Respir Res       Date:  2011-01-05

9.  Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization.

Authors:  Michael I Polkey; Martijn A Spruit; Lisa D Edwards; Michael L Watkins; Victor Pinto-Plata; Jørgen Vestbo; Peter M A Calverley; Ruth Tal-Singer; Alvar Agustí; Per S Bakke; Harvey O Coxson; David A Lomas; William MacNee; Stephen Rennard; Edwin K Silverman; Bruce E Miller; Courtney Crim; Julie Yates; Emiel F M Wouters; Bartolome Celli
Journal:  Am J Respir Crit Care Med       Date:  2012-12-21       Impact factor: 21.405

10.  Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD.

Authors:  Victor Pinto-Plata; Ciro Casanova; Hana Müllerova; Juan P de Torres; Henneth Corado; Nerea Varo; Elizabeth Cordoba; Salah Zeineldine; Hildegarde Paz; Rebeca Baz; Miguel Divo; Felipe Cortopassi; Bartolome R Celli
Journal:  Respir Res       Date:  2012-08-20
View more
  4 in total

1.  Sleep disruption as a predictor of quality of life among patients in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS).

Authors:  Michelle R Zeidler; Jennifer L Martin; Eric C Kleerup; Hartmut Schneider; Michael N Mitchell; Nadia N Hansel; Krishna Sundar; Helena Schotland; Robert C Basner; J Michael Wells; Jerry A Krishnan; Gerard J Criner; Stephanie Cristenson; Samuel Krachman; M Safwan Badr
Journal:  Sleep       Date:  2018-05-01       Impact factor: 5.849

2.  The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium.

Authors:  Bartolome Celli; Kay Tetzlaff; Gerard Criner; Michael I Polkey; Frank Sciurba; Richard Casaburi; Ruth Tal-Singer; Ariane Kawata; Debora Merrill; Stephen Rennard
Journal:  Am J Respir Crit Care Med       Date:  2016-12-15       Impact factor: 21.405

Review 3.  Research Priorities in Pathophysiology for Sleep-disordered Breathing in Patients with Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Research Statement.

Authors:  Atul Malhotra; Alan R Schwartz; Hartmut Schneider; Robert L Owens; Pamela DeYoung; MeiLan K Han; Jadwiga A Wedzicha; Nadia N Hansel; Michelle R Zeidler; Kevin C Wilson; M Safwan Badr
Journal:  Am J Respir Crit Care Med       Date:  2018-02-01       Impact factor: 21.405

4.  Downhill walking influence on physical condition and quality of life in patients with COPD: A randomized controlled trial.

Authors:  Azar Moezy; Azadeh Erfani; Ali Mazaherinezhad; Seyed Ali Javad Mousavi
Journal:  Med J Islam Repub Iran       Date:  2018-06-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.